Sign up USA
Proactive Investors - Run By Investors For Investors

Pfizer tops Q4 hopes but lowers guidance for 2016

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.
Pfizer tops Q4 hopes but lowers guidance for 2016
Pfizer is merging with Allergan

--- adds share price---

Pharma giant Pfizer (NYSE:PFE) beat expectations in its fourth quarter but tempered forecasts for the coming year.

The firm reported on Tuesday that fourth-quarter earnings halved compared to the previous year to US$61mln, or 10 cents per share (EPS), from US$1.22bn, or 19 cents per share.

However, the results include three months of legacy Hospira global operations, Pfizer said, and adjusted EPS was 53 cents per share, slightly ahead of hopes.

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.

But for, 2016, the company said it expects "significant negative currency impact related to Venezuela."

Excluding the effects of its merger with Allergan, Pfizer said it expects adjusted EPS of US$2.20 to US$2.30, including the impact of currency headwinds, below estimates of US$2.38 per share.

Before the resumption of trading on Wall Street, shares were trading 1.7% lower in the pre-market trading, before nudging 0.77% higher in the regular session at US$30.21.

View full PFE profile View Profile

Pfizer Timeline

Related Articles

Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
scientist in a lab
September 27 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use